title: [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
abstract: Hepatocellular carcinoma (HCC) is the most frequent cause of mortality in patients with liver cirrhosis. There are no prospective series from a single tertiary hospital in Spain.
  
  
  METHODS
  We performed a prospective study of patients with HCC in our center. Clinical and epidemiological characteristics, diagnostic method, staging according to the Barcelona Clinic Liver Cancer (BCLC) system and treatment were analyzed.
  
  
  RESULTS
  A total of 136 patients were included (80.9% men). The mean age was 66.62 ± 11.68 years and 91.2% were cirrhotic. Hepatitis C virus (HCV) was the leading cause of liver disease (38.97%). The suspected diagnosis was established by a surveillance program in 63.2%. Noninvasive American Association criteria for the Study of Liver Diseases (AASLD) were the main diagnostic method (73.5%). According to the BCLC, 58.1% were in the early stage (0-A), 21.3% in stage B, 12.5% in stage C and 8.1% in stage D. Early stage patients had followed a surveillance program more frequently than those with non-early stages (79.75% versus 44.35%, p <0.001). Potentially curative initial treatment was used in 45.58%, the most common treatment being percutaneous ethanol injection (23.13%).
  
  
  CONCLUSIONS
  Most patients with HCC in our hospital have cirrhosis, the most frequent cause being HCV. HCC surveillance in at-risk patients could increase diagnosis of HCC at an early stage. We achieved an early diagnosis in more than half of cases. The most common initial treatment was percutaneous therapy.
authors.affiliation: Servicio de Aparato Digestivo, Complejo Hospitalario de Toledo, España.
authors.forename: Rafael
authors.initials: R
authors.lastname: Gómez Rodríguez
authors.forename: Marta
authors.initials: M
authors.lastname: Romero Gutiérrez
authors.forename: Concepción
authors.initials: C
authors.lastname: González de Frutos
authors.forename: Tomás
authors.initials: T
authors.lastname: de Artaza Varasa
authors.forename: Gema
authors.initials: G
authors.lastname: de la Cruz Perez
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Ciampi Dopazo
authors.forename: Carlos
authors.initials: C
authors.lastname: Lanciego Pérez
authors.forename: Ana Zaida
authors.initials: AZ
authors.lastname: Gómez Moreno
mesh_terms: D000368:Aged; D000437:Alcoholism / Q000453:epidemiology; D001557:Benzenesulfonates / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D055088:Early Detection of Cancer; D000431:Ethanol / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000453:epidemiology; D006801:Humans; D008103:Liver Cirrhosis / Q000453:epidemiology; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D016031:Liver Transplantation / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use; D015911:Sclerotherapy; D000077157:Sorafenib; D013030:Spain / Q000453:epidemiology
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000431:Ethanol; D000077157:Sorafenib